Evobright is a new Biotech Startup located in vienna. We develop innovative medicines for patients with solid tumors based on bispecific antibodies (Evobodies). Evobodies activate an infection sensor on cancer cells which are then recognized and destroyed by gamma delta T cells, which initiate a comprehensive anti-infection immune response against the tumor. Thus, Evobright`s technology will prolong and improve the lives of patients world-wide.